title: Phase I study of vorinostat in combination with standard CHOP in patients with newly diagnosed peripheral T-cell lymphoma.
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Oki
authors.forename: Anas
authors.initials: A
authors.lastname: Younes
authors.forename: Amanda
authors.initials: A
authors.lastname: Copeland
authors.forename: Fredrick
authors.initials: F
authors.lastname: Hagemeister
authors.forename: Luis E
authors.initials: LE
authors.lastname: Fayad
authors.forename: Peter
authors.initials: P
authors.lastname: McLaughlin
authors.forename: Jatin
authors.initials: J
authors.lastname: Shah
authors.forename: Nathan
authors.initials: N
authors.lastname: Fowler
authors.forename: Jorge
authors.initials: J
authors.lastname: Romaguera
authors.forename: Larry W
authors.initials: LW
authors.lastname: Kwak
authors.forename: Barbara
authors.initials: B
authors.lastname: Pro
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D006877:Hydroxamic Acids / Q000008:administration & dosage*; D016411:Lymphoma, T-Cell, Peripheral / Q000188:drug therapy*; D011241:Prednisone / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome; D014750:Vincristine / Q000009:adverse effects / Q000627:therapeutic use; D000077337:Vorinostat
chemical_list: D006877:Hydroxamic Acids; D000077337:Vorinostat; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone